（编辑 袁冠琳） 证券日报网讯 冠昊生物11月17日在互动平台回答投资者提问时表示，安润®可降解泪小管栓是公司子公 司聚明生物自主研发的新一代干眼治疗产品，适用于角膜屈光、白内障等手术源性干眼的临时性泪道封 闭治疗。目前业务处于起步阶段，未来经营情况存在一定的不确定性，请投资者理性投资，注意风险。 公司将积极把握市场机遇，提升产品竞争力。公司产品研发方面的进展以及市场竞争力详情敬请关注公 司定期报告。 ...

Core Viewpoint - The company is actively developing a new generation of dry eye treatment products, specifically the Anrun® biodegradable tear duct plug, which is designed for temporary tear duct occlusion in patients undergoing corneal refractive surgery and cataract surgery. The market potential for this product is currently being assessed as the business is in its early stages, indicating some uncertainty in future operations [2]. Group 1 - The Anrun® biodegradable tear duct plug is a product developed by the company's subsidiary, Juming Biotechnology [2]. - The product targets temporary tear duct occlusion treatment for patients with surgery-induced dry eye conditions [2]. - The company acknowledges that its business is in the initial phase, which brings a level of uncertainty regarding future operational performance [2]. Group 2 - The company aims to seize market opportunities and enhance product competitiveness moving forward [2].